Previous studies have shown that the mechanisms of crizotinib resistance in patients with ROS1 fusion-positive NSCLC are mainly divided into two categories: on-target mechanisms involving mutations in the ROS1 kinase domain and off-target mechanisms involving the activation of other signaling pathways11–14. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.